desk
Share
Glenmark Pharmaceuticals has said that its formulation manufacturing facility located at Chhatrapati Sambhaji Nagar (Aurangabad), Maharashtra has successfully cleared the US Food and Drug Administration (USFDA) inspection with no objections. The unit was inspected from September 9 to September 20, 2024, in conclusion the USFDA has issued Form 483 with no objections. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence in specialty generics and OTC business.
The drugmaker reported a consolidated profit of Rs 340.27 crore in the first quarter of FY25, up sharply from Rs 14.48 crore in the same quarter a year ago. Income from operations grew 6.85 per cent year-on-year to Rs 3,244.19 crore in the quarter ended June 30, 2024. Stock performance On Friday, the company's stock closed 2.11 per cent lower at Rs 1,615. In the last one year, the company's stock has seen a gain of 95.12 per cent. The 52-week high of the stock is Rs 1,769.60.
--Advertisement--
_415750157_124x80.png)
_1939818503_124x80.jpg)
